Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $130,672.50 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 5,250 shares of the business’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $24.89, for a total transaction of $130,672.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Benjamin Hohl also recently made the following trade(s):

• On Monday, October 28th, Benjamin Hohl sold 6,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $28.56, for a total transaction of $178,500.00.
• On Friday, October 18th, Benjamin Hohl sold 814 shares of Enliven Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $24,420.00.
• On Friday, October 4th, Benjamin Hohl sold 10,218 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $281,097.18.
• On Monday, October 7th, Benjamin Hohl sold 1,270 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $34,937.70.
• On Friday, September 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.27, for a total transaction of $103,147.50.
• On Monday, September 30th, Benjamin Hohl sold 2,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.33, for a total transaction of $50,660.00.

Enliven Therapeutics Stock Up 0.4 %

Enliven Therapeutics stock opened at $23.71 on Thursday. The company has a market capitalization of $1.16 billion, a PE ratio of -12.48 and a beta of 1.02. The firm has a fifty day simple moving average of $26.78 and a two-hundred day simple moving average of $24.14. Enliven Therapeutics, Inc. has a twelve month low of $9.80 and a twelve month high of $30.03.

Wall Street Analyst Weigh In

ELVN has been the subject of several research reports. Robert W. Baird upped their target price on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. HC Wainwright reissued a “buy” rating and issued a $37.00 price target on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.

Hedge Funds Weigh In On Enliven Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ELVN. FMR LLC raised its stake in shares of Enliven Therapeutics by 10.6% during the third quarter. FMR LLC now owns 6,296,179 shares of the company’s stock valued at $160,804,000 after acquiring an additional 601,611 shares during the last quarter. First Turn Management LLC bought a new position in shares of Enliven Therapeutics during the second quarter valued at about $9,657,000. Janus Henderson Group PLC raised its stake in shares of Enliven Therapeutics by 43.0% during the third quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company’s stock valued at $26,611,000 after acquiring an additional 313,019 shares during the last quarter. Ally Bridge Group NY LLC bought a new position in shares of Enliven Therapeutics during the third quarter valued at about $5,998,000. Finally, Marshall Wace LLP bought a new position in shares of Enliven Therapeutics during the second quarter valued at about $4,489,000. 95.08% of the stock is owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.